ArticleEuropean radiology2018
Article in European radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02076503 (Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status), which is not on this map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature.European urology oncology · 2021Pooled it
- Diagnostic Performance of PET/CT Using 18F-FACBC in Prostate Cancer: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- [European journal of nuclear medicine and molecular imaging · 2021Trial
- [The Journal of urology · 2020Trial
- Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study.AJR. American journal of roentgenology · 2020Trial
- Pelvic lymph node dissection in prostate cancer: current evidence, controversies, and future directions.Annals of medicine · 2026Review
- Article
- The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer.Biomedicines · 2022Review
- Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer.Cancers · 2022Review
- Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends.Cancers · 2021Review
- Utility ofAJR. American journal of roentgenology · 2021Article
- MRI/PET Imaging in elevated PSA and localized prostate cancer: a narrative review.Translational andrology and urology · 2021Review
- An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases.European journal of nuclear medicine and molecular imaging · 2021Article
- 18F-Fluciclovine Positron Emission Tomography in Prostate Cancer: A Systematic Review and Diagnostic Meta-Analysis.Diagnostics (Basel, Switzerland) · 2021Review
- Incidental Detection of Lung Adenocarcinoma Presenting as an Anterior Mediastinal Mass on 18F-Fluciclovine PET/CT in a Patient With Primary Prostate Cancer.Clinical nuclear medicine · 2020Article
- Salvage Pelvic Lymph Node Dissection and Current State of Imaging for Recurrent Prostate Cancer: Does a Standard Exist?Current urology reports · 2020Review
- Diagnostic Performance ofThe world journal of men's health · 2020Article
- Performance ofEuropean journal of nuclear medicine and molecular imaging · 2020Article
- [Urology · 2019Article
- Multimodality Imaging of Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Review
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the diagnostic potential of simultaneous
methodsHigh-risk prostate cancer patients (n=28) underwent simultaneous
resultsPatient- and region-based sensitivity/specificity for detection of pelvic LN metastases was 40 %/87.5 % and 35 %/95.7 %, respectively, for MRI and 40 %/100 % and 30 %/100 %, respectively, for PET. LN metastases in true-positive regions were significantly larger than metastases in false-negative regions. PET-positive stage N1 patients had higher metastatic burden than PET-negative N1 patients.
conclusionSimultaneous KEY POINTS: •
Indexed as
Identifiers
29294158What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.